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Abstract 
We report the clinical outcomes of 83 patients with acute lymphoblastic leukemia (median age, 46 
years; range, 18-75 years) treated at our institution between 1999 and 2011. Treatment refers to 
clinical trials open for accrual at the time of diagnosis or to institutional guidelines. Upfront 
allografting was considered for younger high-risk patients. Seventy-eight of 83 (94%) patients 
achieved complete remission after induction, although 53% of them eventually relapsed. Forty of 70 
patients younger than 61 years underwent allografting. The median follow-up was 7.4 years (range, 
0.2-15.0 years). Overall, the 5-year overall survival (OS) and event-free survival (EFS) were 40% 
and 39%, respectively. In patients undergoing transplantation, OS and EFS at 5 years were both 
53%, whereas in a nontransplantation setting, both OS and EFS were 35% at 5 years (P = .044 for 
both OS and EFS). By multivariate analysis, the independent predictors of OS and EFS were age 
and leukocytosis in the overall population and allografting in young patients. 
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Introduction 
Adult acute lymphoid leukemia (ALL) is a rare disease with an estimated incidence of about 1 in 
100,000.
1
 With the current intense chemotherapy protocols, 90% of patients younger than 55 years 
achieve postinduction remission, but the majority invariably experience relapsed disease.
1
 
Postremission strategies have included prolonged chemotherapy, autografting, and allografting. 
More recently, the introduction of targeted therapy with tyrosine kinase inhibitors (TKIs)
2, 3, 4 and 5
 
and monoclonal antibodies
6, 7, 8 and 9
 have changed the scenario of ALL treatment. Furthermore, 
persistence or reappearance of minimal residual disease (MRD) evaluated by molecular methods 
after induction may soon lead to risk-oriented treatment guidelines.
10
 
The policy for the treatment of ALL at our institution has been that of enrolling patients in 
multicenter clinical trials and considering an allograft in first remission in young high-risk patients. 
The primary aim of this single-institution study was to compare the results of our policy with those 
reported in the current literature (http://ClinicalTrials.gov: NCT01785914). 
Methods 
Patients 
Between December 1999 and December 2011, 88 consecutive adult patients were diagnosed with 
ALL at the Division of Hematology at Città della Salute e della Scienza Hospital, University of 
Torino, Torino, Italy according to standard criteria.
11
 Five of 88 patients were excluded from the 
analysis because they received only supportive care owing to their poor clinical condition. All died 
shortly after diagnosis. Complete remission (CR), relapse, and refractory disease were defined 
according to published criteria.
12
 Molecular analysis with qualitative and quantitative polymerase 
chain reaction has been performed since 2001, with minimal target sensitivity of 10
−4
, as previously 
described.
13
 Data were retrospectively and anonymously collected through the review of medical 
records. The study was approved by the Institutional Review Board of the Città della Salute e della 
Scienza Hospital of Torino, Torino, Italy according to the Declaration of Helsinki 
(http://ClinicalTrials.gov: NCT01785914). Patients were stratified by standard or high risk of 
progression by cytogenetic analysis, immunophenotyping, and presenting clinical features.
14
 
Induction Chemotherapy 
Patients were induced with chemotherapy regimens in prospective clinical trials active at the time of 
diagnosis or according to institutional guidelines for those not eligible for controlled trials. An 
allograft from a related or an unrelated donor was considered in all patients younger than 61 years 
in first complete remission (CR) if they were at high risk or in second CR if a standard risk of 
relapse existed. 
Allografting 
Myeloablative regimens consisted of cyclophosphamide/total body irradiation (TBI),
15
 
cyclophosphamide-busulfan, and thiotepa/busulfan/cyclophosphamide, whereas reduced-intensity 
conditioning regimens consisted of thiotepa/cyclophosphamide.
16
 A low-dose total body 
irradiation–based nonmyeloablative regimen (200 cGy) was used in 2 patients with a high 
comorbidity score.
17
 Acute and chronic graft-vs.-host disease (GVHD) was diagnosed and graded 
according to common criteria.
18 and 19
 
Statistical Analysis 
Primary end points were overall survival (OS) and event-free survival (EFS) from the time of 
diagnosis. OS was defined as the time from diagnosis to death from any cause, whereas EFS was 
defined as the time from diagnosis to disease progression/relapse or death from any cause, 
whichever occurred first. Patient characteristics were tested using the Fisher exact test for 
categorical variables and the Mann-Whitney test for continuous variables. OS and EFS were 
calculated using the Kaplan-Meier method and compared with the log-rank test; 2 landmark 
analyses for OS were performed at minimum and median times from diagnosis to allografting. For 
univariate analyses, OS and EFS were analyzed by the Cox proportional hazards model, comparing 
the 2 risk factors by the Wald test and calculating 95% confidence intervals (CIs). Univariate and 
multivariate analyses were carried out on the entire patient cohort and on patients younger than 61 
years who were potential candidates for an allograft. Risk factors included age (> 60 years vs. 36-60 
years vs. ≤ 35 years), year of diagnosis (2008-2011 vs. 2004-2007 vs. 2000-2003), leukocytosis (B 
lymphocytic acute leukemia [ALL], > 30 × 10
9
/L vs. < 30 × 10
9
/L; T lymphocytic acute leukemia 
[T-ALL], > 100 × 10
9
/L vs. < 100 × 10
9
/L), cytogenetic features and immunophenotyping at 
diagnosis (high vs. standard risk), presence of the Bcr-Abl rearrangement, allografting (yes vs. no), 
grade II/IV acute GVHD and chronic GVHD. Allografting and acute and chronic GVHD were 
treated as time-dependent variables. For patients undergoing transplantation, cumulative incidences 
of acute and chronic GVHD and nonrelapse mortality (NRM) were estimated by Gray competing 
risk regression models as previously described. 
20
 NRM was defined as death without previous 
relapse. Death without acute GVHD was considered a competing risk for acute GVHD, whereas 
death without chronic GVHD was considered a competing risk for chronic GVHD, and relapse was 
considered a competing risk for NRM. All P values were 2-sided at the conventional 5% 
significance level. Data were analyzed by IBM SPSS Statistics, version 21.0.0 (SPSS, Chicago, IL) 
and R 2.15.2 package cmprsk (The R Foundation for Statistical Computing, Vienna, Austria). 
Results 
Study Population 
Clinical characteristics of 83 evaluable patients are summarized in Table 1. Two HIV-positive 
patients receiving retroviral treatment were included. Overall by leukocytosis, cytogenetic analysis, 
and immunophenotyping,
1, 11 and 14
 57 of 83 (69%) patients were at high risk of progression, and 19 
had a standard risk of progression. By cytogenetic analysis only, 36 patients had a high risk 
(Table 1). In the 57 high-risk patients, only 34 (60%) were eligible for an allograft as part of first-
line treatment because of age or comorbidities, or both. 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Patient Characteristics 
 
Abbreviations: B-ALL = B-lymphocytic acute lymphoblastic leukemia; CR = complete 
remission; NK-ALL = natural killer-acute lymphoblastic leukemia; T-ALL = T-lymphocytic 
acute lymphoblastic leukemia; WBC = white blood cell. 
a 
Missing data. 
Chemotherapy 
All patients received induction and consolidation chemotherapy followed by either maintenance 
therapy or allografting. Seventy-nine of 83 (95%) patients were enrolled in prospective clinical 
trials, whereas 4 patients were treated according to institutional guidelines (Table 2).
10 and 21
 All 
first-line treatments included steroids, vincristine, methotrexate, daunorubicin, and L-asparaginase. 
The 2 patients with HIV were treated with protocols 2 and 3 (Table 2); 1 of these patients required 
dose reduction because of liver toxicity. 
 
Table 2. Treatment Protocols 
 
Abbreviation: it = intrathecal. 
Transplant Preparative Regimens, Stem Cell Source, and GVHD 
Overall, in the 70 patients younger than 61 years, 40 (57%) underwent an allograft procedure 
(Table 1) because of a high risk of relapse (n = 34), disease recurrence (n = 5), or disease refractory 
to first-line treatment (n = 1) (Table 1). Donors were HLA identical siblings (n = 22), unrelated (n = 
15) or haploidentical siblings (n = 3). Conditioning regimens were myeloablative in the majority of 
cases (n = 38), and in 37 of 40 (93%) cases, granulocyte-colony stimulating factor–mobilized 
peripheral blood was the source of stem cells. Overall, 19 of 40 patients eventually died, and in 16 
of the 19 patients, the cause of death was disease recurrence. The cumulative incidence of NRM 
was 2.5% at 1 year and 7.5% at both 3 and 5 years, whereas the relapse incidence was 17.5% and 
40.5%, respectively. Cumulative incidences of grade II-IV acute and extensive chronic GVHD were 
41.0% and 35.9%, respectively. No grade IV acute GVHD occurred. Only 2 patients underwent 
nonmyeloablative transplantation; both underwent transplantation in first CR but eventually died 
because of disease recurrence. 
Disease Response 
Overall, 78 of 83 (94%) patients achieved CR, and in 74 of 78 (95%) of them, CR was achieved 
within 4 weeks from induction. However, 41 of 78 (53%) eventually experienced relapse of disease. 
Five patients never achieved CR and died of disease progression at a median time of 3 months from 
diagnosis (range, < 1-8). 
Disease-Specific Markers 
Disease-specific molecular markers were identified in 34 of the 73 patients evaluated (47%). 
Twenty patients carried t(9;22) (Ph+ ALL) and 2 additional patients carried the Bcr-Abl 
rearrangement without t(9;22). Other markers included a monoclonal T-cell receptor in 7 patients, 
MLLA-F4 in 2, FR2-JH in 2 and FR3-JK in 1 patient each. In 20 of 22 (90%) patients with the 
Bcr/Abl rearrangement diagnosed after 2002, treatments also included tyrosine kinase inhibitors 
(TKIs). Imatinib was given upfront in 17 of 20 patients (85%), and 6 of them later switched to 
dasatinib for persistent disease or molecular progression; 1 also received nilotinib and ponatinib. 
Four of 20 patients (20%) were treated with imatinib after induction because of persistence of 
MRD, and 1 patient also received dasatinib. 
MRD and Allografting 
Twenty of 40 patients who received an allograft had a molecular marker. MRD was evaluated in 19 
of 20 patients during pretransplantation workup: 10 did not have MRD and 9 had MRD at the time 
of transplantation. During follow-up, 8 of 10 patients without MRD maintained a molecular 
response, whereas 3 of 9 patients with MRD achieved a status of no MRD after transplantation, and 
4 still had MRD (data missing in 4 patients). 
Clinical Outcomes 
Overall Patient Population 
After a median follow-up of 7.4 years (range, 0.2-15.0 years), 41% of the patients were alive, and 5-
year OS and EFS were 40% and 39%, respectively (Figure 1). The 2 patients with HIV tolerated the 
treatment but eventually died of disease recurrence at 38 and 11 months, respectively. OS at 5 years 
was 15% in patients older than 60 years, 38% in those between 35 and 60 years, and 58% in 
patients younger than 35 years (P = .001), whereas 5-year EFS was 8%, 38%, and 58% (P < .001), 
respectively. OS and EFS at 5 years in patients with leukocytosis were 26% and 22%, respectively, 
and 51% and 51%, respectively, in those without leukocytosis (P = .008 and P = .002, respectively). 
Year of diagnosis and type of chemotherapy did not correlate with OS or EFS. Patients at high risk 
of relapse/progression by cytogenetic analysis showed a trend toward worse OS and EFS when 
compared with those at low risk (22 and 16 months, respectively, vs. not reached). 
 Figure 1. (A) Overall Survival (OS) and (B) Event-Free Survival (EFS) From Diagnosis of the 
Study Population 
Univariate and multivariate analyses are shown in Table 3. By multivariate analysis, age and 
leukocytosis were statistically significant predictors of OS and EFS. Year of diagnosis was not 
associated with either OS (P = .656) or EFS (P = .636). The impact of high-risk cytogenetic results 
did not reach statistical significance. 
    Table 3.    Univariate and Multivariate Analyses of the Entire Patient Cohort (N = 83) 
 Abbreviations: CI = confidence interval; EFS = event-free survival; HR = hazard ratio; OS = 
overall survival. 
Patients Younger Than 61 Years of Age 
Five-year OS and EFS were both 53% in patients undergoing transplantation and 35% in patients 
not undergoing transplantation (P = .044 for both OS and EFS). Median time from diagnosis to 
allografting was 6 months (range, 4-10 months). Landmark analysis at 4 months from diagnosis 
showed a 5-year OS of 53% in 40 patients undergoing transplantation and of 36% in patients not 
undergoing transplantation (n = 28; P = .065), whereas landmark analysis at 6 months showed an 
OS of 53% and 38%, respectively (n = 40 and n = 26; P = .139). 
At 5 years, both OS and EFS were 68% versus 50% (P = .543 and P = .459, respectively) in 
patients with MRD (n = 10) and patients without MDR (n = 9) before allografting. Of the 8 patients 
with a molecular marker who were not eligible for transplantation, all patients with MRD (n = 4) 
died, whereas all patients without MRD (n = 2) were alive at follow-up (data missing in 2 patients). 
Univariate and multivariate analyses (Table 4) showed that allografting was the only variable 
correlated with longer OS and EFS. No impact of acute and chronic GVHD was observed. 
Table 4. Univariate and Multivariate Analyses in Patients Younger Than 61 Years (n = 70) 
 Abbreviations: CI = confidence interval; EFS = event-free survival; HR = hazard ratio; 
hSCT = hematopoietic stem cell transplantation; GVHD = graft-vs.-host disease; OS = 
overall survival. 
a 
Treated as time-dependent variables. 
Discussion 
Current treatment of adult ALL represents an evolving paradigm. Our study summarized a 12-year 
experience in 83 consecutive patients with ALL diagnosed and treated at the Città della Salute e 
della Scienza Hospital in Torino, Italy. The aim was to compare the results of our “real-life” 
experience with that reported in the current literature, despite the limitation of the retrospective 
analysis. 
With a median follow up of 7.4 years, OS at 5 years was 40%, which was similar to other 
reports.
1 and 22
 Leukocytosis only was a strong predictor of survival. Patients with poor prognostic 
cytogenetic results showed a trend for a worse outcome, most likely because of the sample size and 
a larger proportion of high-risk patients (60%), by cytogenetic analysis, who underwent 
allografting. Similarly, the poor prognostic role of the Bcr/Abl rearrangement did not emerge. 
Pediatric patients with ALL show better survival than adults.
1
 Poorer outcomes in adults are 
multifactorial but are likely related to a higher incidence of adverse cytogenetic features and a 
lessened ability to tolerate intensive pediatric-inspired chemotherapy regimens. These factors carry 
even more weight in elderly patients who are rarely eligible for allografting.
23
 However, 5-year OS 
has recently improved about 12% from the early 1980s to the early 2000s, especially in patients ≤ 
60 years,
22
 but our study period was too short to appreciate a significant difference. In our study, 
patients younger than 35 years gained a significant benefit regarding both OS and EFS, as 
confirmed by multivariate analyses (P = .03). 
Several reports showed that high-risk patients are the most suitable candidates for 
allografting.
24 and 25
 Most of our patients younger than 61 years (57%) underwent an allograft 
procedure. Although mostly prepared with myeloablative conditioning, NRM was extremely low. 
This finding may partially be explained by a high incidence of early relapse (17.5% at 1 year), 
transplantation in first CR (34 of 40 patients), and young median age (41 years). The incidence of 
acute and chronic GVHD (41.0% and 35.9%, respectively) was consistent with previously 
published data.
24, 25, 26 and 27
 Allografting was correlated with a significant advantage regarding both 
OS and EFS compared with chemotherapy alone. Moreover, 2 landmark analyses at 4 and 6 months 
(minimum and median time from diagnosis to transplantation, respectively) suggested an advantage 
in patients undergoing transplantation, although the difference did not reach statistical significance. 
By multivariate analysis, allografting was confirmed as an independent predictor of outcome. 
Predictors of longer survival were age and leukocytosis in the whole study population. 
Several points of interest have recently been raised in ALL treatment: 
• 
MRD monitoring represents an independent risk factor,
10 and 28
 and it may help to identify 
patients who would most benefit from an allograft. 
• 
Reduced-intensity conditionings could broaden transplantation eligibility to older 
patients.
26 and 27
 
• 
TKIs can be regarded as the first targeted therapy in ALL.
2, 3, 4 and 5
 Their optimal role 
remains to be defined in both transplant-eligible and non–transplant-eligible patients. 
• 
Monoclonal antibodies have been recently introduced: rituximab, which improved survival 
in CD20-positive ALL
6
; blinatumomab, a biallelic T cell engaging the CD3-CD19 
monoclonal antibody, resulted in overall response rates of 40% to 50% in a refractory 
population with relapsed disease,
7 and 8
 and inotuzubab ozogamicin, a CD33 monoclonal 
antibody bound to calicheamicin resulted in 55% CR in a similar setting.
9
 
In conclusion, our “real-life” report suggests that our single-institution experience is similar to that 
reported by other groups and confirms the role of allografting. Hopefully, the introduction of novel 
targeted therapies as a bridge to transplantation or as maintenance in high-risk patients, or both, 
may better control the disease and improve transplantation outcomes, leading to a higher cure rate. 
Clinical Practice Points 
• 
Adult acute lymphoid leukemia is a rare disease. 
• 
With the current intense chemotherapy protocols, 90% of patients younger than of 55 years 
achieve postinduction remission, but the majority invariably experience relapsed disease. 
• 
Postremission strategies have included prolonged chemotherapy, autografting, and 
allografting. 
• 
We reported the clinical outcomes of 83 patients with acute lymphoblastic leukemia, median 
age 46 years (range, 18-75 years) years, treated at a single institution between 1999 and 
2011. Five additional patients were excluded because they died shortly after diagnosis 
before starting therapy. 
• 
The aim was to compare the results of our “real-life” experience with that reported in the 
current literature. Most of the patients were at high risk of relapse and were enrolled in 
active clinical trials at the time of diagnosis. 
• 
Overall, the 5-year survival was 40%. With the limitation of a retrospective analysis, our 
experience confirmed the impact of age and leukocytosis on patient survival in the whole 
population and the key role of allografting in patients younger than 61 years. 
• 
The introduction of monitoring MRD and novel targeted therapies (such as TKIs and 
monoclonal antibodies) as a bridge to transplantation or as maintenance, or both, in high-
risk patients may better control the disease and improve transplantation outcomes, leading to 
a higher cure rate. 
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